Simon Lynch

Part of STERIS Plc (Ireland), AMSCO International, Inc. makes infection control and decontamination products. The company is based in Pittsburgh, PA. AMSCO International was acquired by STERIS Corp. on May 13, 1996 for $619.50 million.

Immunex Corporation is a leading biopharmaceutical company dedicated to improving lives through immune system science innovation

Nura, Inc. discovers and develops pharmaceutical products. It offers products for the treatment of neurodegenerative diseases such as Parkinson's & Alzheimer's diseases and behavioural disorders such as depression, anxiety, schizophrenia, obesity, and addiction. The company was founded in August 2003 and is headquartered in Seattle, WA.

Raven Biotechnologies, Inc. engages in the development of antibody therapeutics for the treatment for cancer, autoimmune disorders and infectious diseases. Its products are used in treatment of gastrointestinal, lung, colon, pancreatic, prostate, breast, brain, and ovarian cancer. The company was founded in 1999 and is headquartered in South San Francisco, CA.

Cercano Management LLC /Private Equity/ (Cercano Management) is a venture capital subsidiary of Cercano Management LLC founded in 1986 by Paul Gardner Allen. The firm is headquartered in Bellevue, Washington.

Cornell University is an educational institution that offers undergraduate and post graduate programs. It was founded in 1865 and is based in Ithaca, NY.

Kallyope, Inc. engages in developing drugs and consumer products. Its specialties include biotechnology, gut-brain axis, nutrition, and pharmaceuticals. The company was founded by Thomas P. Maniatis, Charles Zuker and Richard Axel in 2014 and is headquartered in New York, NY.

Twinstrand Biosciences, Inc. develops technologies to detect ultra-rare variants. It uses technology for new generation of clinical diagnostics and tools for scientific discovery. The company was founded by Jesse Salk and Michael Schmitt in 2015 and is headquartered in Seattle, WA.

LifeSprout, Inc. commercializes synthetic material made of hydrogel and polyester nanofibers. It aims to change the treatment of soft tissue losses with an injectable synthetic material that mimics living tissue. The company was founded by Russell Martin, Hai-Quan Mao, Justin Sacks, and Sashank Reddy in 2018 and is headquartered in Baltimore, MD.

Lycia Therapeutics, Inc. is a biotechnology company, which engages in the developing technology that utilizes lysosome-targeting chimeras. It uses LYTACs platform to discover and provide therapeutics that degrade extracellular and membrane-bound proteins that drive a range of difficult-to treat diseases, including cancers and autoimmune conditions. The company was founded by Carolyn R. Bertozzi in 2019 and is headquartered in San Diego, CA.